Skip to main content
Equibles
RNAZ logo

RNAZ · Transcode Therapeutics, Inc.

Track RNAZ — free

Use RNAZ with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RNAZ

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.28 -0.06 (-2.56%) At close · Aug 27
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”
View the 10-Q filed Aug 14, 2026
Market Cap
$39.62M
Shares
16.93M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.28 Open$2.35 Day$2.27–2.41 52W close$2.28–15.23 Avg vol 30d31K Short int31K · 0.2% float · 1.5d Short vol43% Last earningsApr 1, 2022 DataMay 2025–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on May 15, 2025; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −70%
below
Price vs 50-day avg −58%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −57%
trailing
6-month return −77%
trailing
YTD return −67%
this year
Relative strength −92%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.18% of float · ▲ +9.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 3-yr range
Squeeze score 37
low risk · 0–100
Fundamentals
Strong
EPS growth +96%
Y/Y
Free cash flow $-19.5M
Balance sheet $15.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 100%
annualized · 1-yr
Max drawdown −85%
past year
ATR 21.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−70% Bearish
Price vs 50-day avg
−58% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.18% of float · ▲ +9.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $15
vs 200-day avg -70% vs 50-day avg -58%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RNAZ
Transcode Therapeutics, Inc.
this stock
$39.62M -66.6% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +4.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
8
% held
0.2%
Net QoQ
+2.6K sh
Top holder
Yorkville Advisors Global…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Rising
Shares short
30.9K
Days to cover
1.5d
Change
+2.7K sh
View
Short Volume
Short vol %
43%
As of
Aug 27, 2026
Short Total
View
Fails to Deliver
FTD shares
439
Value
$3.7K
As of
Jul 8, 2026
View
Off-Exchange
Off-exchange %
50.7%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-34.7M
EPS diluted
$-52.59
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
19
View
Exempt Offerings
Offering
$8.0M
Filed
Dec 12, 2024
View
Earnings & Events
Earnings Calls
Last call
Apr 1, 2022
View
Investor Relations
Upcoming events
1
View

Performance

Raw-price comparisons begin at the captured split on May 15, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
RNAZ -23.2% -56.6% -76.8% -50.0% -66.6%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY -24.3% -60.5% -91.5% -53.2% -79.7%
Key facts CIK 1829635 CUSIP 89357L501 13F (30d) 8 filings 8 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)